Jubilant Pharmova receives ₹87.31 crore GST show cause notice from Mysore

0 min read | Published on 01 Sept 2026, 12:51 PM |Updated on 01 Sept 2026, 01:11 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Jubilant Pharmova received a ₹87.31 crore GST show cause notice from Mysore authorities
The demand covers FY23 and includes ₹33.58 crore in tax, interest, and penalty
Allegations involve ineligible ITC and discrepancies in e-waybill records
Company contests the notice as legally incorrect and expects no financial impact

*this image is generated using AI for illustrative purposes only.

Jubilant Pharmova has received a show cause notice proposing a GST demand of ₹87.31 crore from the Assistant Commissioner of Commercial Taxes (Enforcement)-4, Mysore, for FY23.

Notice details

The notice, dated August 31, 2026, cites issues including alleged ineligible input tax credit (ITC), excess ITC availed, and differential tax liability based on e-waybill records.

The following table summarises the breakdown of the proposed demand:

Component	Amount
GST (Tax)	₹33.58 crore
Interest	₹20.15 crore
Penalty	₹33.58 crore
Total	₹87.31 crore

Company response

Jubilant Pharmova stated that the notice is factually and legally incorrect and was issued without proper verification or opportunity to respond. The company claims to have a strong case in its favour and expects no financial or operational impact.

It is currently preparing a detailed reply with documentary evidence to contest the demand before the Mysore tax authorities.

Historical Stock Returns for Jubilant Pharmova

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.59%	+0.22%	-3.26%	+4.43%	-11.57%	+36.39%

How might the outcome of this GST dispute impact Jubilant Pharmova's quarterly cash flows and working capital management?

Could this regulatory scrutiny signal a broader tightening of GST enforcement on input tax credits within the Indian pharmaceutical sector?

What are the potential implications for Jubilant Pharmova's credit ratings if the tax liability is upheld or if prolonged litigation ensues?

Jubilant Pharmova

View Company Insights

View All News

Jubilant Pharmova faces ₹105.5 Cr GST demand over IGST refund claim

1 min read | Published on 28 Aug 2026, 10:15 AM |Updated on 28 Aug 2026, 10:18 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Jubilant Pharmova received a CGST show cause notice proposing a total demand of ₹105.5 crore
The demand includes ₹52.75 crore in tax and an equal penalty for ineligible IGST refunds
The notice targets subsidiary Jubilant Generics for violations in FY21-22
Company disputes the notice as factually incorrect and plans to contest it

*this image is generated using AI for illustrative purposes only.

Jubilant Pharmova disclosed receipt of a show cause notice from the Joint Commissioner of Central Goods and Services Tax (CGST) in Roorkee, proposing a total financial demand of ₹105.5 crore. The notice, issued on August 27, 2026, targets the company’s wholly-owned subsidiary, Jubilant Generics Limited.

The tax authority alleges that Jubilant Generics inadmissibly claimed Integrated GST (IGST) refunds under Rule 96 while simultaneously availing benefits under the Advance Authorisation scheme. This action is cited as a violation of Rule 96(10) of the CGST Rules, 2017, covering the financial years 2020-21 and 2021-22.

Breakdown of Proposed Demand

The show cause notice proposes specific monetary penalties alongside the principal tax demand. The interest component remains unquantified at this stage.

Component	Amount (₹ Crore)
GST Tax Demand	52.75
Penalty	52.75
Interest	Not Quantified

Company Response

Jubilant Pharmova stated that the notice is factually and legally incorrect. The company claims the authority issued the notice without properly verifying facts or examining the issue. Management asserts it has a strong case on its merits.

The company plans to file a detailed reply before the Joint Commissioner, CGST Division, Roorkee, to contest the demand. Consequently, Jubilant Pharmova expects no material financial or operational impact from this development.

Historical Stock Returns for Jubilant Pharmova